Abstract:Abstract Background Enhancer of zesta homologue 2 (EZH2) is an essential component of polycomb repressive complex 2 (PRC2) that contributes to tumor progression and chemo-resistance. The aim of this study was to comprehensively assess the prognostic value of EZH2 across the morphologic and molecular spectra of high-grade serous ovarian carcinoma (HGSOC) by utilizing both immunohistochemistry (IHC) and proteogenomic technologies. Methods IHC of EZH2 was performed using a tissue microarray of 79 HGSOC scored (+/−) for lymphovascular invasion (LVI), tumor-infiltrating lymphocytic aggregates ≥1 mm (TIL) and architectural growth patterns. The association of EZH2 H-score with response to therapy and overall survival was evaluated by tumor features. We also evaluated EZH2 transcriptional (RNA sequencing) and protein (mass spectrometry) expression from bulk tumor samples from 336 HGSOC from The Cancer Genome Atlas (TCGA). EZH2 expression and co-expression networks were compared by clinical outcomes. Results For HGSOC without TIL (58%), EZH2 expression was almost 2-fold higher in platinum resistant tumors (P = 0.01). Conversely, EZH2 was not associated with platinum resistance among TIL+ HGSOC (P = 0.41). EZH2 expression was associated with reduced survival for tumors with LVI (P = 0.04). Analysis of TCGA found higher EZH2 expression in immunoreactive and proliferative tumors (P = 6.7 × 10− 5) although protein levels were similar across molecular subtypes (P = 0.52). Both mRNA and protein levels of EZH2 were lower in platinum resistant tumors although they were not associated with survival. Co-expression analysis revealed EZH2 networks totaling 1049 mRNA and 448 proteins that were exclusive to platinum sensitive or resistant tumors. The EZH2 network in resistant HGSOC included CARM1 which was positively correlated with EZH2 at both mRNA (r = 0.33, p = 0.003) and protein (r = 0.14, P = 0.01) levels. Further, EZH2 co-expression with CARM1 corresponded to a decreased prognostic significance of EZH2 expression in resistant tumors. Conclusions Our findings demonstrate that EZH2 expression varies based on its interactions with immunologic pathways and tumor microenvironment, impacting the prognostic interpretation. The association between high EZH2 expression and platinum resistance in TIL- HGSOC warrants further study of the implications for therapeutic strategies.

EZH2 mutation is associated with the development of visceral metastasis by enhancing proliferation and invasion and inhibiting apoptosis in breast cancer cells

Morphologic and Molecular Correlates of EZH2 As a Predictor of Platinum Resistance in High-Grade Ovarian Serous Carcinoma.

EZH2 G553C significantly increases the risk of brain metastasis from lung cancer due to salt bridge instability

Integration of Estrogen and Wnt Signaling Circuits by the Polycomb Group Protein EZH2 in Breast Cancer Cells.

Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis

Enhancer of Zeste Homolog 2 is Involved in the Proliferation of Endometrial Carcinoma.

Integrative proteomics reveals the role of E3 ubiquitin ligase SYVN1 in hepatocellular carcinoma metastasis

Polycomb Protein Ezh2 Activates Wnt/Beta-Catenin Signaling To Promote Hepatocellular Carcinoma Development

Enhancer of zeste homolog 2 blockade by RNA interference is implicated with inhibited proliferation, invasion and promoted apoptosis in endometrial carcinoma.

EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via integrin β1-FAK activation

EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates

EZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic features

Ezh2 Promotes Cell Migration And Invasion But Not Alters Cell Proliferation By Suppressing E-Cadherin, Partly Through Association With Malat-1 In Pancreatic Cancer

Prognostic Significance of Histone Methyltransferase Enhancer of Zeste Homolog 2 in Patients with Cervical Squamous Cell Carcinoma

Progress in Relationship Between EZH2 and Gastric Cancer

Abstract 2435: EZH2 engages TGFb signaling to promote breast cancer bone metastasis via Integrin b1-FAK activation

EZH2 Participates in Malignant Biological Behavior of Epithelial Ovarian Cancer Through Regulating the Expression of BRCA1

Enhancer of Zeste Homolog 2 (EZH2) Promotes Tumour Cell Migration and Invasion Via Epigenetic Repression of E-cadherin in Renal Cell Carcinoma.

Ezh2 Promotes Invasion and Metastasis of Laryngeal Squamous Cells Carcinoma Via Epithelial-Mesenchymal Transition Through H3k27me3

Ezh2 Promotes Malignant Behaviors Via Cell Cycle Dysregulation And Its Mrna Level Associates With Prognosis Of Patient With Non-Small Cell Lung Cancer

EZH2 Exacerbates Breast Cancer by Methylating and Activating STAT3 Directly